Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
2006-12-12
2006-12-12
O'Hara, Eileen B. (Department: 1646)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C435S230000, C435S069100, C435S069700, C530S350000, C424S185100, C424S192100, C536S023400, C536S023500
Reexamination Certificate
active
07148061
ABSTRACT:
The present invention provides a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD) of a TNF-like receptor. Also provided by this invention is a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD), wherein the PLAD is selected from the group consisting of: the PLAD of a TNF-R, the PLAD of p60, the PLAD of p80, the PLAD of Fas (CD95/APO-1), the PLAD of TRAIL receptors, the PLAD of LTβR, the PLAD of CD40, the PLAD of CD30, the PLAD of CD27, the PLAD of HVEM, the PLAD of OX40 and the PLAD of DR4. TNF-R, p60, p80, Fas, TRAIL receptor, LTβR, CD40, CD30, CD27, HVEM, OX40, DR4, TROY, EDAR, XEDAR, DCR3, AITR, 4-1BB, DR3, RANK, TACI, BCMA, DR6, DPG, DR5, DCR1 AND DCR2 are all members of the TNF receptor superfamily or the TNF-like receptor family. The invention also provides the PLAD for other members of the TNF receptor superfamily. The polypeptides of the present invention can be utilized to inhibit oligomerization of members of the TNF receptor superfamily. These polypeptides can also be utilized to inhibit ligand binding to members of the TNF receptor superfamily. The present invention also provides a composition comprising an inhibitor of TNF receptor oligomerization. Further provided by this invention are members of the TNF receptor superfamily that are lacking a PLAD.
REFERENCES:
patent: 5503995 (1996-04-01), Khudyakov et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633145 (1997-05-01), Feldmann et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5830731 (1998-11-01), Seed et al.
patent: 5866372 (1999-02-01), Stein et al.
patent: 6569664 (2003-05-01), Gatanaga et al.
patent: 07/289266 (1995-11-01), None
patent: WO 96/20206 (1996-07-01), None
patent: WO 95/21915 (1995-08-01), None
patent: WO 98/01555 (1998-01-01), None
patent: WO 98/18824 (1998-05-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/38525 (1999-08-01), None
Ashkenazi and Dixit, “Death Receptors: Signaling and Modulation,”Science281:1305-1308 (Aug. 28, 1998).
Banner et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation,”Cell73(3):431-435 (May 7, 1993).
Blezinger et al., “Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene,”Nat. Biotechnol.17(4):343-348 (Apr. 1999).
Blondelle et al., “Rapid identification of compounds with enhanced antimicrobial activity by using conformationally defined combinatorial libraries,”Biochem. J.313:141-147 (1996).
Boldin et al., “Self-association of the “Death Domains” of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects,”J. Biol. Chem.270(1):387-391 (1995).
Boldin et al., “A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain,”J. Biol. Chem.270:7795-7798 (1995).
Boldin et al., “Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death,” 85:803-815 (Jun. 14, 1996).
Chan et al., “A Domain in TNF Receptors That Mediates Ligand-Independent Receptor Assembly and Signaling,”Science288(5475):2351-2354 (Jun. 30, 2000).
Chen et al., “Mapping the Domain(s) Critical for the Binding of Human Tumor Necrosis Factor-α to Its Two Receptors,”J. Biol. Chem.270(6):2874-2878 (1995).
Chinnaiyan et al., “FADD, a Novel Death Domain-Containing Protein, Interacts with the Death of Fas and Initiates Apoptosis,”Cell81(4):505-512 (May 19, 1995).
Corcoran e tal., “Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor. Involvement of individual cysteine-rich repeats,”Eur. J. Biochem.223:831-840 (1994).
Cosma et al., “Mutations in the Extracellular Domain Cause RET Loss of Function by a Dominant Negative Mechanism,”Mol. Cell. Biol.18(6):3321-3329 (1998).
Declercq et al., “Cooperation of Both TNF Receptors in Inducing Apoptosis: Involvement of the TNF Receptor-Associated Factor Binding Domain of the TNF Receptor 75,”J. Immunol.161:390-399 (1998).
Dörner et al., “The Synthesis of Peptidomimetic Combinatorial Libraries Through Successive Amide Alkylations,”Bioorg. Med. Chem.4(5):709-715 (May 1996).
Drappa et al., “FasGene Mutations In The Canale-Smith Syndrome, An Inherited Lymphoproliferative Disorder Associated With Autoimmunity,”N. Engl. J. Med.335(22):1643-1649 (Nov. 28, 1996).
Eichler et al., “Peptide, Peptidomimetic, and Organic Synthesis Combinatorial Libraries,”Med Res Rev15(6):481-496 (Nov. 1995).
Fakhral et al., “Construction and Characterization of Retroviral Vectors for Interleukin-2 Gene Therapy,”J. Immunother20(6):437-448 (1997).
Fisher et al., “Dominant Interfering Fas Gene Mutations Impair Apoptosis in a Human Autoimmune Lymphoproliferative Syndrome,”Cell81(6):935-946 (Jun. 16, 1995).
Gadella et al., “Oligomerization of Epidermal Growth Factor Receptors on A431 Cells Studied by Time-resolved Flourescence Imaging Microscopy. A Stereochemical Model for Tyrosine Kinase Receptor Activation,”J. Cell. Biol.129(6):1543-1558 (Jun. 1995).
Gorman et al., “A recombinant adenovirus that directs secretion of biologically active κ-bungarotoxin from mammalian cells,”Bran Res. Mol. Brain Res.44(1):143-146 (1997).
Guo et al., “Fluorescence Resonance Energy Transfer Reveals Interleukin (IL)-1-dependent Aggregation of IL-1 Type I Receptors That Correlates with Receptor Activation,”J. Biol. Chem270(46):27562-27568 (Nov. 17, 1995).
Haridas et al., “Overexpression of the p80 TNF Receptor Leads to TNF-Dependent Apoptosis, Nuclear Factor-κB Activation, and c-Jun Kinase Activation,”J. Immunol.160:3152-3162 (1998).
Heller et al., “The p70 Tumor Necrosis Factor Receptor Mediates Cytotoxicity,”Cell70(1):47-56 (Jul. 10, 1992).
Herskowitz, “Functional inactivation of genes by dominant negative mutations,”Nature329(6136):219-222 (Sep. 17, 1987).
Horie and Watanabe, “CD30: expression and function in health and disease,”Semin. Immunol.10(6):457-470 (Dec. 1998).
Hsu et al., “Differential Expression and Ligand Binding Properties of tumor necrosis factor receptor chimeric mutants,”J. Biol. Chem.268(22):16430-16436 (1993).
Hsu et al., “TNF-Dependent Recruitment of the Protein Kinase RIP to the TNF Receptor-1 Signaling Complex,”Immunity4:387-396 (1996).
Huang et al., “NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain,”Nature384(6640):638-641.
Hughes et al., “Delivery of a Secretable Adenosine Deainase Through Microcapsules—A Novel Approach to Somatic Gene Therapy,”Hum. Gene Ther.5(12):1445-1455 (Dec. 1994).
Hymowitz et al., “Triggering Cell Death: The Crystal Structure of Apo2I/TRAIL in a Complex with Deatch Receptor 5,”Mol. Cell4:563-571 (Oct. 1999).
Jackson et al., “Autoimmune Lymphoproliferative Syndrome with Defective Fas: Genotype Influences Penetrance,”Am. J. Hum. Genet.64:1002-1014 (Apr. 1999).
Jiang et al., “Prevention of Constitutive TNF Receptor 1 Signaling by Silencer of Death Domains,”Science283(5401):543-546 (Jan. 22, 1999).
Jones et al., “TNF Recruits TRADD to the Plasma Membrane But Not the trans-Golgi Network, the Principal Subcellular Location of TNF-R1,”J. Immunol.162:1042-1048 (1999).
Jouanguy et al., “A humanIFNGR1small deletion hotspot associated with dominant susceptib
Chan Francis Ka-Ming
Lenardo Michael J.
Siegel Richard M.
Needle & Rosenberg P.C.
O'Hara Eileen B.
The United States of America as represented by the Department of
LandOfFree
Identification of a novel domain in the tumor necrosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification of a novel domain in the tumor necrosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of a novel domain in the tumor necrosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3720189